ASSOCIATE PROFESSOR GUY HINGSTON ON MINDACT: FEWER AUSTRALIAN WOMEN WILL NOW NEED CHEMOTHERAPY FOR BREAST CANCER

You can read in full in The Oncology News here:

http://oncologynews.com.au/associate-professor-guy-hingston-on-mindact-less-australian-women-will-now-need-chemotherapy-for-breast-cancer/

 

 

 

How breast cancer patients can be spared chemotherapy with the MammaPrint test

Read my interview with The Sydney Morning Herald here:

http://www.smh.com.au/national/health/breast-cancer-patients-could-be-spared-chemotherapy-with-new-genetic-test-study-shows-20160826-gr1tj6.html

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

Dr Martine Piccart and her colleagues have today published in the New England Journal of Medicine their results of the landmark international prospective randomized Microarray In Node negative Disease May Avoid Chemotherapy (MINDACT) study. MINDACT assessed MammaPrint genomic testing of nearly 7,000 women with early breast cancer. In Australia, Associate Professor Guy Hingston says that this is the biggest news in breast cancer management in 2016!

Read the article in The New England Journal of Medicine here: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1602253